Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines.
Journal: JCO oncology practice
Published: September 24, 2025
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
Journal: Melanoma research
Published: June 16, 2023
A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Journal: American journal of clinical oncology
Published: June 02, 2023
A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.
Journal: American journal of clinical oncology
Published: June 14, 2022
An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer.
Journal: American journal of clinical oncology
Published: June 13, 2022
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
Journal: Nature medicine
Published: December 09, 2021
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Journal: Frontiers in oncology
Published: November 19, 2021
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: October 27, 2021
Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Journal: American journal of clinical oncology
Published: July 26, 2021
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Journal: Gynecologic oncology
Published: November 30, 2020
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
Journal: Gynecologic oncology
Published: April 21, 2020
Last Updated: 09/26/2026